Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study

[1]  T. Haferlach,et al.  Monitoring of minimal residual disease in acute myeloid leukemia , 2005, Cancer.

[2]  M. Tallman,et al.  Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. , 2007, Blood.

[3]  A. Venditti,et al.  Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. , 2007, Haematologica.

[4]  W. Berdel,et al.  New molecular therapy targets in acute myeloid leukemia. , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[5]  Hartmut Döhner,et al.  Acute myeloid leukaemia , 2006, The Lancet.

[6]  M. Béné,et al.  A Multicenter Randomized Comparison of Maintenance Treatment with Androgens in Elderly Acute Myeloid Leukemia after ICL Regimen as Induction Therapy: Results of the Goelams-2002 Study. , 2006 .

[7]  M. Parmar,et al.  Comparison of Survival Curves , 2006 .

[8]  C. Bloomfield,et al.  Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. , 2006, Hematology. American Society of Hematology. Education Program.

[9]  W. Berdel,et al.  The molecular pathogenesis of acute myeloid leukemia. , 2005, Critical reviews in oncology/hematology.

[10]  A. Bosi,et al.  Allogeneic stem cell transplantation. , 2005, Transplantation proceedings.

[11]  C. Bloomfield,et al.  Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Hiddemann,et al.  Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. , 2003, Blood.

[14]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[15]  A. Órfão,et al.  Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. , 2001, Blood.

[16]  D. Grimwade,et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[17]  Claudia Schoch,et al.  Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients , 2001, British journal of haematology.

[18]  S. Ichiyama,et al.  Flow cytometric method for enumeration and classification of reactive immature granulocyte populations. , 2000, Cytometry.

[19]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.

[20]  R. Gray,et al.  A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial , 1999, British journal of haematology.

[21]  E. Solary,et al.  Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients , 1998, Leukemia.

[22]  F Lacombe,et al.  Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia , 1997, Leukemia.

[23]  A. Erath,et al.  Proposed reference method for peripheral-blood monocyte counting using fluorescence-labelled monoclonal antibodies. , 1996, Cytometry.

[24]  C. Pui,et al.  Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. , 1995, Blood.

[25]  G. Browman,et al.  Predicting remission outcome in acute non-lymphocytic leukemia: general principles and their application to residual marrow leukemia. , 1992, Leukemia research.

[26]  M. Buyse,et al.  Cancer Clinical Trials: Methods and Practice. , 1985 .

[27]  N. Gallagher,et al.  Neutralization of the Biological Activity of Erythropoietin by Immune Sera * , 1964, British journal of haematology.

[28]  Ruemke Cl.  Laboratory aids. Variability of results in differential cell counts on blood smears. , 1960 .

[29]  C. L. Ruemke.  Laboratory aids. Variability of results in differential cell counts on blood smears. , 1960, Triangle; the Sandoz journal of medical science.

[30]  D.,et al.  Regression Models and Life-Tables , 2022 .